A rare breast tumor; Adenomyoepithelioma: a case report and review of the literature

Adenomyoepithelioma is rare benign breast neoplasia characterized by the proliferation of both epithelial and myoepithelial cells of themammary lobules and ducts. This tumour, which does not have specific risk factors and radiological findings, is mostly seen in advancedages. This tumour, which occurs with the biphasic proliferation of epithelial and myoepithelial cells, also contains normal breast lobules andducts. This tumour is very difficult to diagnose and includes many radiological and pathological pitfalls. Although malignant degenerationhas been reported in the literature, it is a rare condition. In this study, we present a rare case with radiologically suspicious findings andpathologically reported as adenomyoepithelioma

Ulcerative colitis may be a risk factor for sensorineural hearing loss

Introduction: Inner ear involvement of inflammatory bowel disease (IBD), which causes sensorineural hearing loss (SNHL) is acute and bilateral and arises in a short period of weeks to months in the active period of the disease. We aimed to determine the frequency of SNHL in patients with UC and CD and to evaluate the relationship between audiological features and clinical findings in IBD. Material and Method: The present study included 53 IBD patients and 20 healthy control patients who were followed up in the gastroenterology outpatient clinic of Abant Izzet Baysal University Hospital between January and May 2020 and accepted to participate in the study. Tympanometry, otoscopy, and audiometry examinations were performed. Results: There was no significant difference in terms of gender and age between the IBD and control groups. While there was no significant difference in air and bone conduction in both ears in patients with CD, there was a significant difference between both conductions in UC (p: 0.0001 in the left ear, p: 0.004 in the right ear). SNHL was detected in 45.2% (n:14) of UC patients and 13.6% (n:3) of CD patients in audiometry. Three of our UC patients had moderate, one had moderately severe, and one had profound hearing loss. Conclusion: SNHL has been detected in a significant number of UC patients. Also, the hearing functions deteriorate significantly as the age of the patients and the duration of the disease increases. UC patients with a long-term disease or older patients should be evaluated for SNHL

ÇÖLYAK HASTALIĞINDA FİBROMİYALJİ SIKLIĞI VE FİBROMİYALJİNİN HASTALAR ÜZERİNE ETKİSİNİN DEĞERLENDİRİLMES

AMAÇ: Çölyak hastalığı, gluten ilişkili bir enteropati olmakla birlikte malabsorbsiyona bağlı bütün vücudu etkileyebilen bir hastalıktır. Diğer yandan antijen maruziyeti sebebiyle kronik inflamasyona da zemin hazırlamaktadır. Kronik inflamasyonun vücutta sistemik etkilerinin olduğu bilinmektedir. Çölyak hastalığının sistemik etkileri farklı mekanizmalar üzerinden fibromiyalji sendromunu (FMS) tetikliyor olabilir. Çalışmamızın amacı Çölyak hastalarında FMS prevalansını belirlemek ve FMS’nin Çölyak hastaları üzerindeki etkisini değerlendirmektir. GEREÇ VE YÖNTEM: Çalışmaya 1 Şubat-10 Haziran 2019 tarihleri arasında Gastroenteroloji kliniğimize başvuran 24 Çölyak hastası (7 aktif, 17 Çölyak diyeti altında) ve 20 kontrol gönüllü olarak dahil edildi. FMS tanısı için 2010 American College of Rheumatology kriterleri kullanıldı. WSPI (yaygın ağrı indeksi), SSS (somatik semptom ağırlık skoru) ve toplamından FMS skoru hesaplandı. Bütün katılımcılara fibromiyalji etki anketi uygulandı. Veriler istatistiksel olarak karşılaştırıldı. BULGULAR: Çölyak hastaları ve kontrol grubunda FMS sıklığı birbirleriyle karşılaştırıldığında anlamlı farklılık saptanmadı; Çölyak hastalarında %12,5, gönüllü kontrol grubunda %5 (p: 0,61). Kadın ve erkeklerdeki FMS sıklığı benzerdi. Gruplar arasında WSPI, SSS ve FMS skorları açısından anlamlı fark yoktu. FMS etki skalası skorları yönünden FMS olanlar ile olmayanlar karşılaştırıldığında gönüllü kontrol grubunda anlamlı fark yoktu (23,9±18,8 ve 21,5±0; p: 0,90). Çölyak hastalığı olanlarda, FMS etki skoru FMS olanlarda olmayanlara göre daha yüksek olmasına rağmen anlamlılık düzeyine ulaşmamıştır (51,9±25,5 ve 28,5±17,7; p: 0,25). SONUÇ: Türk toplumunda Çölyak hastalarında FMS sıklığını gösteren ilk çalışmadır. Normal popülasyona göre Çölyak hastalığında FMS sıklığı artmamaktadır. Çölyak hastalığında aktivitenin FMS üzerine etkisi yoktur. FMS tanısı olan Çölyak hastalarında olmayanlara göre hayat kalitesi daha çok etkilenmektedir. Daha geniş bir popülasyonda yapılacak çalışmalara ihtiyaç vardır

Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19

Background and aim: The aim of this study is to evaluate whether the long-term (?4 weeks) use of proton pump inhibitors (PPIs) is arisk factor for intubation requirement and mortality in patients hospitalized for COVID-19.Materials and methods: In this multicentric retrospective study, a total of 382 adult patients (?18 years of age) with confirmedCOVID-19 who were hospitalized for treatment were enrolled. The patients were divided into two groups according to the periodsduring which they used PPIs: the first group included patients who were not on PPI treatment, and the second group included thosewho have used PPIs for more than 4 weeks.Results: The study participants were grouped according to their PPI usage history over the last 6 months. In total, 291 patients did notuse any type of PPI over the last 6 months, and 91 patients used PPIs for more than 4 weeks. Older age (HR: 1.047, 95% CI: 1.026–1.068),current smoking (HR: 2.590, 95% CI: 1.334–5.025), and PPI therapy for more than 4 weeks (HR: 1.83, 95% CI: 1.06–2.41) were foundto be independent risk factors for mortality.Conclusion: The results obtained in this study show that using PPIs for more than 4 weeks is associated with negative outcomes forpatients with COVID-19. Patients receiving PPI therapy should be evaluated more carefully if they are hospitalized for COVID-19treatment